Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Invir.IO

Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform

Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform

Published 15 December 2021
Categorized as 2021, 2021, Press release, Invir.IO, Press release, TG4050

Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021

20211109 – Transgene BioInvent SITC BT-001 en

Published 9 November 2021
Categorized as 2021, BT-001, Invir.IO, Press release

Transgene Participates in New Cancer Research Consortium

Transgene Participates in New Cancer Research Consortium

Published 1 September 2021
Categorized as 2021, Press release, Invir.IO, Press release, TG4001, TG4001

Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors (ICIs)

20210608 – IP Invir.IO ICI – EN

Published 8 June 2021
Categorized as 2021, Invir.IO, Press release

Transgene and BioInvent receive IND approval from the U.S. FDA for BT-001, a novel oncolytic virus for the treatment of solid tumors

210527 – Transgene BioInvent_BT001 IND_EN

Published 27 May 2021
Categorized as 2021, BT-001, Invir.IO, Press release

Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastrointestinal carcinomas

K. Bendjama et al. AACR 2021 Read the abstract here – Download the poster here Poster Presentation

Published 9 April 2021
Categorized as -others, 2021, Invir.IO, Publication, TG6002

Transgene to Present its Immuno-Oncology Expertise at Upcoming Scientific Conferences

20210302 – Transgene Scientific Conferences

Published 2 March 2021
Categorized as 2021, Invir.IO, Myvac, Press release

Transgene and BioInvent have enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors

20210301 – Transgene BT-001 FPI – EN

Published 1 March 2021
Categorized as 2021, BT-001, Invir.IO, Press release

Transgene and BioInvent receive approval from ANSM to proceed with Phase I/IIa trial of anti-CTLA4-armed oncolytic virus BT-001 in solid tumors

20210119 – ANSM Approval BT-001 EN

Published 19 January 2021
Categorized as 2021, BT-001, Invir.IO, Press release

Transgene and BioInvent receive CTA approval for Phase 1/2a trial of oncolytic virus BT-001 in solid tumors

20201221 – CTA Approval BT-001 – EN

Published 21 December 2020
Categorized as 2020, BT-001, Invir.IO, Press release

Posts pagination

Newer posts Page 1 … Page 3 … Page 6 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu